Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02842021 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis
A Phase 2 study, sponsored by Sol-Gel Technologies.
- Terminated
- Registry status
- Phase 2
- Development phase
- 283
- Enrollment target
NCT02842021: Clinical Trial Phase 2 study, sponsored by Sol-Gel Technologies.
NCT02842021 is a Phase 2 study that was terminated before completion, run by Sol-Gel Technologies. The registered enrollment target is 283 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (113% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02842021, a Phase 2 study, was terminated before completion, sponsored by Sol-Gel Technologies.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 283 participants
- Enrollment target
Study Summary
To assess the efficacy and safety of a combination product S2G6T-1 compared to its monads and vehicle, applied twice daily for 7 days, in the treatment of symptomatic inflammatory interdigital tinea pedis in subjects 12 years of age and older. The results of this study will be utilized to perform power calculations for the Phase 3 pivotal trials.
Primary Outcome
The primary efficacy comparison between S2G6T-1 vs. rest of study arms will be based on the percentage of subjects at day 29 with complete cure of interdigital tinea pedis.mycological cure (i.e. negative dermatophyte culture and negative KOH) and clinical cure (i.e. absence of erythema, scaling and pruritus {scores of 0, each})
Interventions
- DRUG S2G6T-1
- DRUG S2G6T-2
- DRUG S2G6T-3
- DRUG S2G6T-4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 283 participants |
| Start Date | 2016-09 |
| Est. Completion | 2017-10 |
| Phase | Phase 2 |
Why NCT02842021 stopped before completion
NCT02842021 is an interventional study that assigns participants to a tested intervention. The registered 283 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (113% higher).
The record links to 0 conditions, and to 4 interventions - of which S2G6T-1 is the first listed.
NCT02842021 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02842021 about?
NCT02842021 is a clinical study titled "Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis". To assess the efficacy and safety of a combination product S2G6T-1 compared to its monads and vehicle, applied twice daily for 7 days, in the treatment of symptomatic inflammatory interdigital tinea pedis in subjects 12 years of age and older. The results of this study will be utilized to perform po...
What is the current status of trial NCT02842021?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 283 participants. The study started on 2016-09. Estimated completion is 2017-10.
What interventions are being tested in trial NCT02842021?
The interventions under investigation include: S2G6T-1 (DRUG), S2G6T-2 (DRUG), S2G6T-3 (DRUG), S2G6T-4 (DRUG).
Who is sponsoring clinical trial NCT02842021?
This trial is sponsored by Sol-Gel Technologies, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02842021's enrollment target sits among peer trials
283 195th of 2000 higher than 1,806 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06856694 · 283 participants · NA
RCT of NLP-Based Feedback for Improving SDM in Men With Localized Prostate Cancer
- NCT05263206 · 284 participants · Phase 3
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
- NCT05769218 · 284 participants · NA
PrEP and MOUD Rapid Access for Persons Who Inject Drugs: The CHORUS+ Study
- NCT06856577 · 284 participants · Phase 3
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia